AKEEGA™
(niraparib and abiraterone acetate)
JOHNSON & JOHNSON
HK Reg. No. HK-68296 (09 Jul, 2024) &
HK-68295 (09 Jul, 2024)
Composition:2
AKEEGA™ is a combination of niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 (Cytochrome P450 17A1) inhibitor. It is available in 50 mg and 100 mg tablet forms.
Indication:2
AKEEGA™ is indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC).
References
1. TARGRETIN®. HIGHLIGHTS OF PRESCRIBING INFORMATION US 2015. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021055s006lbl.pdf 2. AKEEGA™. Package Insert 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021055s006lbl.pdf 3. LEQEMBI®. HIGHLIGHTS OF PRESCRIBING INFORMATION US 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761269Orig1s001lbl.pdf 4. LITFULO™. HIGHLIGHTS OF PRESCRIBING INFORMATION US 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215830s000lbl.pdf
